FOLH1 and metastatic prostate carcinoma: Actinium-225 (225Ac) was chosen as the radionuclide for alpha-particle therapy (TAT) targeted to the melanocortin 1 receptor for treatment of metastatic uveal melanoma [6], the prostate-specific membrane antigen (PSMA) for metastatic prostate cancer [1], and CD33 for acute myeloid leukemia [7].